Solid Biosciences (SLDB) EBITDA: 2017-2024
Historic EBITDA for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to -$39.9 million.
- Solid Biosciences' EBITDA fell 79.19% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 24.44%. This contributed to the annual value of -$129.7 million for FY2024, which is 24.44% down from last year.
- According to the latest figures from Q4 2024, Solid Biosciences' EBITDA is -$39.9 million, which was down 13.40% from -$35.2 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' EBITDA ranged from a high of -$19.0 million in Q2 2020 and a low of -$39.9 million during Q4 2024.
- Moreover, its 3-year median value for EBITDA was -$26.9 million (2024), whereas its average is -$28.6 million.
- As far as peak fluctuations go, Solid Biosciences' EBITDA skyrocketed by 35.59% in 2023, and later plummeted by 79.19% in 2024.
- Over the past 4 years, Solid Biosciences' EBITDA (Quarterly) stood at -$21.3 million in 2020, then reached -$34.6 million in 2022, then spiked by 35.59% to -$22.3 million in 2023, then tumbled by 79.19% to -$39.9 million in 2024.
- Its EBITDA was -$39.9 million in Q4 2024, compared to -$35.2 million in Q3 2024 and -$27.8 million in Q2 2024.